ADIAL PHARMACEUTI DL-,001

Adial Pharmaceuticals says a leadership change following the September 17, 2026, annual meeting depends on shareholders’ approval of certain proposals. If approved, Cary Claiborne would step down as president and CEO and CFO Vinay Shah would resign; Matthew Davidson is expected to become CEO. The board also plans changes to the size and composition of the board of directors. Separately, Adial has closed the first tranche of a private placement raising $32 million as part of a $64 million financing round and has added the acquisition of Azora, including drug candidate AT177, to its pipeline. » Więcej na de.investing.com

Adial Pharmaceuticals has acquired Azora Therapeutics and added the drug candidate AT177 (an oral aryl‑hydrocarbon‑receptor agonist for ulcerative colitis) to its pipeline. In parallel, Adial completed a private placement raising up to 64 million USD in gross proceeds (about 32 million USD immediately against pre‑funded warrants, and a further 32 million USD upon initiation of the Phase‑1 study). After the transaction, former Adial shareholders will own roughly 7.7%, Azora’s founders about 51%, and the placement investors approximately 41.3% of the diluted company; Coastlands Capital led the financing. Dr. Wendy Young was appointed to the board of directors; proceeds are intended to fund IND‑enabling studies and a Phase‑1a/1b trial for AT177, with Phase‑1 start planned for mid‑2027. » Więcej na de.investing.com

Adial Pharmaceuticals has filed a utility patent application for AD04 with the U.S. patent office and simultaneously requested a prioritized “Track One” review to accelerate the process. AD04 is a serotonin‑3 receptor antagonist for treating alcohol use disorders in patients with certain genotypes identified by a proprietary genetic test. If granted, the patent would provide protection through at least 2045. The company plans a new Phase‑3 trial program for AD04. » Więcej na de.investing.com